Is ORTX or HDV a better dividend investment in 2026?

ORTX currently yields 11.98% with a 5% 5-year dividend growth rate. HDV yields 2.92% with 4.8% growth. The better choice depends on your goal: ORTX offers higher current income.

What is the dividend yield difference between ORTX and HDV?

ORTX has a forward dividend yield of 11.98% ($2.00/share annually). HDV yields 2.92% ($3.96/share annually). The yield gap is 9.06 percentage points.

Home › Compare › ORTX vs HDV

ORTX vs HDV: Dividend Comparison 2026

ORTX yields 11.98% · HDV yields 2.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ORTX wins by $19.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ORTX

● Live price

11.98%

Share price

$16.70

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.1K

Annual income

$2,528.78

Full ORTX calculator →

HDV

iShares Core High Dividend ETF

● Live price

2.92%

Share price

$135.39

Annual div

$3.96

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$24.3K

Annual income

$352.73

Full HDV calculator →

Portfolio growth — ORTX vs HDV

📍 ORTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ORTX	HDV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ORTX + HDV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ORTX pays

HDV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORTX

Annual income on $10K today (after 15% tax)

$1,017.96/yr

After 10yr DRIP, annual income (after tax)

$2,149.46/yr

HDV

Annual income on $10K today (after 15% tax)

$248.52/yr

After 10yr DRIP, annual income (after tax)

$299.82/yr

At 15% tax rate, ORTX beats the other by $1,849.64/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORTX + HDV for your $10,000?

ORTX: 50%HDV: 50%

100% HDV50/50100% ORTX

Portfolio after 10yr

$34.2K

Annual income

$1,440.75/yr

Blended yield

4.21%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORTX buys

HDV buys

No recent congressional trades found for ORTX or HDV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricORTXHDV

Forward yield	11.98% ✓	2.92%
Annual dividend / share	$2.00	$3.96 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$44.1K ✓	$24.3K
Annual income after 10y	$2,528.78 ✓	$352.73
Total dividends collected	$18.5K ✓	$3.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ORTX vs HDV ($10,000, DRIP)

Year	ORTX Portfolio	ORTX Income/yr	HDV Portfolio	HDV Income/yr	Gap
1← crossover	$11,898	$1,197.60	$11,002	$292.38	+$896.00 → ORTX
2	$14,062	$1,331.65	$12,084	$300.36	+$2.0K → ORTX
3	$16,517	$1,470.94	$13,250	$308.02	+$3.3K → ORTX
4	$19,288	$1,614.74	$14,506	$315.35	+$4.8K → ORTX
5	$22,401	$1,762.27	$15,858	$322.35	+$6.5K → ORTX
6	$25,882	$1,912.75	$17,313	$329.04	+$8.6K → ORTX
7	$29,759	$2,065.39	$18,878	$335.42	+$10.9K → ORTX
8	$34,061	$2,219.43	$20,560	$341.49	+$13.5K → ORTX
9	$38,820	$2,374.13	$22,367	$347.25	+$16.5K → ORTX
10	$44,066	$2,528.78	$24,307	$352.73	+$19.8K → ORTX

ORTX vs HDV: Complete Analysis 2026

ORTX — Stock

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Full ORTX Calculator →

HDV — ETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →

📬

Get this ORTX vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORTX vs SCHD ORTX vs JEPI ORTX vs O ORTX vs KO ORTX vs MAIN ORTX vs VYM ORTX vs DVY ORTX vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.